We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+35.87%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$211M
AUM Growth
-$31.9M
(-13%)
Cap. Flow
-$83.2M
Cap. Flow
% of AUM
-39.42%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek Logistics
DKL
|
+$1.29M |
| 2 |
Western Midstream Partners
WES
|
+$970K |
| 3 |
Viper Energy
VNOM
|
+$883K |
| 4 |
Canadian Natural Resources
CNQ
|
+$761K |
| 5 |
EPR Properties
EPR
|
+$729K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Barings BDC
BBDC
|
+$2.49M |
| 2 |
Prospect Capital
PSEC
|
+$2.37M |
| 3 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$2.34M |
| 4 |
Nuveen Credit Strategies Income Fund
JQC
|
+$2.3M |
| 5 |
WhiteHorse Finance
WHF
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Capital Southwest
CSWC
$1.46B
| $637K | 0.3% |
47,284
-116,520
| -71% | -$1.51M |
|
102
Vertex Pharmaceuticals
VRTX
$122B
| $633K | 0.3% |
2,179
-502
| -19% | -$136K |
|
103
Alnylam Pharmaceuticals
ALNY
$37.2B
| $632K | 0.3% |
4,269
-733
| -15% | -$98.8K |
|
|
ESPR
104
DELISTED
Esperion Therapeutics
ESPR
| $632K | 0.3% |
12,310
+5,075
| +70% | +$212K |
|
|
WPG
105
DELISTED
Washington Prime Group Inc.
WPG
| $630K | 0.3% |
83,247
+32,959
| +66% | +$242K |
|
106
Halozyme
HALO
$9.67B
| $629K | 0.3% |
23,455
-7,541
| -24% | -$170K |
|
107
BioMarin Pharmaceuticals
BMRN
$11.7B
| $624K | 0.3% |
5,063
-2,274
| -31% | -$226K |
|
|
108
Nuveen Credit Strategies Income Fund
JQC
$704M
| $616K | 0.29% |
105,506
-389,391
| -79% | -$2.3M |
|
109
Ultragenyx Pharmaceutical
RARE
$2.65B
| $615K | 0.29% |
7,864
-5,910
| -43% | -$391K |
|
|
SAGE
110
DELISTED
Sage Therapeutics
SAGE
| $615K | 0.29% |
14,782
+6,710
| +83% | +$244K |
|
|
ONC
111
BeOne Medicines Ltd
ONC
$33.8B
| $615K | 0.29% |
3,265
-78
| -2% | -$12.7K |
|
|
IMMU
112
DELISTED
Immunomedics Inc
IMMU
| $613K | 0.29% |
17,305
-92
| -0.5% | -$2.69K |
|
113
Regeneron Pharmaceuticals
REGN
$70.1B
| $612K | 0.29% |
981
-671
| -41% | -$381K |
|
114
Agios Pharmaceuticals
AGIO
$2.21B
| $607K | 0.29% |
11,354
-1,246
| -10% | -$57.7K |
|
115
Karyopharm Therapeutics
KPTI
$161M
| $607K | 0.29% |
2,137
-205
| -9% | -$60.6K |
|
116
Nektar Therapeutics
NKTR
$2.4B
| $605K | 0.29% |
1,741
-103
| -6% | -$32.1K |
|
117
Incyte
INCY
$23.7B
| $604K | 0.29% |
5,813
-611
| -10% | -$58.9K |
|
118
Ironwood Pharmaceuticals
IRWD
$649M
| $604K | 0.29% |
58,560
+12,557
| +27% | +$129K |
|
|
SGEN
119
DELISTED
Seagen Inc. Common Stock
SGEN
| $602K | 0.29% |
3,541
-1,627
| -31% | -$243K |
|
|
BPMC
120
DELISTED
Blueprint Medicines
BPMC
| $597K | 0.28% |
7,658
+2,822
| +58% | +$191K |
|
|
BGX
121
Blackstone Long-Short Credit Income Fund
BGX
$135M
| $592K | 0.28% |
49,128
-141,758
| -74% | -$1.62M |
|
122
Neurocrine Biosciences
NBIX
$17.8B
| $587K | 0.28% |
4,807
-515
| -10% | -$56.9K |
|
|
ALXN
123
DELISTED
Alexion Pharmaceuticals
ALXN
| $580K | 0.27% |
5,166
-478
| -8% | -$50.7K |
|
124
Amgen
AMGN
$203B
| $579K | 0.27% |
2,456
-33
| -1% | -$7.53K |
|
|
BGB
125
Blackstone Strategic Credit 2027 Term Fund
BGB
$500M
| $576K | 0.27% |
50,420
-167,919
| -77% | -$1.83M |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, Virtus ETF Advisers held 499 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 8.5% of the portfolio.
Virtus ETF Advisers withdrew a net $83.2M in Q2 2020, closing 57 positions and reducing 218 holdings. Its most notable exit was Tallgrass Energy, LP Class A Shares, an estimated $1.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 20% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Verastem worth $342K.
- Virtus ETF Advisers's largest Q2 2020 buy was Verastem: 16,584 shares worth $342K.
- Virtus ETF Advisers added most to Delek Logistics in Q2 2020, an estimated $1.29M increase.
- Virtus ETF Advisers's biggest Q2 2020 reduction was Barings BDC, cutting an estimated $2.49M.
- Virtus ETF Advisers fully exited Tallgrass Energy, LP Class A Shares in Q2 2020, selling an estimated $1.22M.
- Virtus ETF Advisers's ten largest holdings make up 8.5% of its $211M portfolio in Q2 2020.
- Virtus ETF Advisers opened 89 new positions and closed 57 in Q2 2020.
- Virtus ETF Advisers's portfolio value fell 13% quarter-over-quarter to $211M.
Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.